PolyPeptide's board, acting through its independent and non-conflicted members, unanimously recommended shareholders accept
Semaglutide (Wegovy and Ozempic) is an FDA-approved GLP-1 agonist that is used to treat obesity, type 2 diabetes, and weight-related health conditions such as metabolic dysfunction-associated steatohepatitis (MASH)
The commenter was concerned this could suppress patient volume, exacerbate disparities, and create challenges in recruiting clinical talent, ultimately undermining patient safety outcomes
doi:10.1002/cjoc.201300061 ZhouW, Shultz JW, Murphy N, Hawkins EM, Bernad L, Good T, Moothart L, Frackman S, Klaubert DH, Bulleit RF, Wood KV (2006) Electrophilic aromatic substituted luciferins as bioluminescent probes for glutathione S-transferase assays